Glaucoma

Glaucoma, the leading cause of irreversible blindness worldwide, is gaining increased attention due to projected increases in cases and potential therapeutic advancements. New estimates predict that the UK will see a rise to 1.6 million glaucoma cases by 2060, significantly higher than the current 1.1 million, driven primarily by an aging population. This highlights the growing burden of the disease. Simultaneously, research is exploring potential treatments. A US research team has demonstrated that an investigational drug, already proven safe in humans and used in neuroscience research, can slow the progression of glaucoma and prevent vision loss in animal models. This discovery offers a potential avenue for new treatments, although further research and clinical trials are needed to determine its efficacy and safety in humans. The combination of rising prevalence and potential therapeutic breakthroughs makes glaucoma a significant and relevant area of ongoing research and public health concern.